ROIV: Mosliciguat's breakthrough data and brepocitinib's promising DM launch drive major pipeline momentum
Mosliciguat delivered record efficacy in pulmonary hypertension, prompting plans for broader indications and rapid phase III enrollment. Brepocitinib's DM launch is progressing steadily, with strong physician enthusiasm and significant market potential. Key pipeline catalysts include NIU and RA dat…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.